This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Race Oncology June 2022 Quarterly Investor Briefing
Race Oncology CEO Phillip Lynch and CSO Dr Daniel Tillett present Race’s June 2022 Quarterly Investor Briefing followed by a Q&A session.